D. Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target Avita’s Recell technology has shown “promising results” in clinical trials for a variety of soft tissue and skin-related indications and Avita is “poised for significant growth” from expanding market penetration into trauma wounds, surgical wounds, and “slowly but surely chronic wounds” as awareness of the technology increases and adoption grows in hospitals and burn centers worldwide, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCEL:
